Trial · NCT03167242
Participant flow84
How many started, completed or left each group, period by period.
1 to 20 of 84
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 Day | 12 | |
| Overall Study | STARTED | Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | 51 | |
| Overall Study | STARTED | Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 Day | 51 | |
| Overall Study | STARTED | Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 Days | 51 | |
| Overall Study | STARTED | Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 Days | 54 | |
| Overall Study | STARTED | Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 Days | 51 | |
| Overall Study | STARTED | Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 Days | 52 | |
| Overall Study | STARTED | Part A - Cohort 7: Coartem | 27 | |
| Overall Study | STARTED | Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | 53 | |
| Overall Study | STARTED | Part B - Cohort 2: KAF 400 mg and LUM 960 mg QD for 2 Days | 53 | |
| Overall Study | STARTED | Part B - Cohort 3: KAF 400 mg and LUM 960 mg QD for 3 Days | 45 | |
| Overall Study | STARTED | Part B - Cohort 4: Coartem | 24 | |
| Overall Study | Full Analysis Set (FAS) | PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 Day | 12 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | 51 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 Day | 51 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 Days | 51 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 Days | 54 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 Days | 51 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 Days | 52 | |
| Overall Study | Full Analysis Set (FAS) | Part A - Cohort 7: Coartem | 27 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03167242/flow